Andere talen Verastem, Inc.

Aandelen

VSTM

US92337C2035

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,38 ^USD	+1,79%		-4,67%	+15,23%

18/04	Verastem Oncology kondigt veranderingen in leiding aan	CI
14/03	Verastem, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Verastem Names John Hayslip as Chief Medical Officer	18/04
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	18/04
Verastem Oncology Announces Executive Changes	18/04
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	05/04
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	18/03
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Verastem: Q4 Earnings Snapshot	14/03
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	14/03
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	11/03
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation	05/03
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer	05/03
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	05/03
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	05/03
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	29/01
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers	29/01
Sector Update: Health Care Stocks Mixed Premarket Friday	19/01
Sector Update: Health Care	19/01
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer	19/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Verastem, Inc.

Aandelen

VSTM

US92337C2035

Andere talen

Filters